2017

Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy
Louis D, Aldape K, Brat D, Capper D, Ellison D, Hawkins C, Paulus W, Perry A, Reifenberger G, Figarella-Branger D, Wesseling P, Batchelor T, Cairncross J, Pfister S, Rutkowski S, Weller M, Wick W, von Deimling A
ACTA NEUROPATHOL. 2017;133(1):1-3.

2016

MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties
Dietl S, Schwinn S, Dietl S, Riedel S, Deinlein F, Rutkowski S, von Bueren A, Krauss J, Schweitzer T, Vince G, Picard D, Eyrich M, Rosenwald A, Ramaswamy V, Taylor M, Remke M, Monoranu C, Beilhack A, Schlegel P, Wölfl M
BMC CANCER. 2016;16(1):115.

Evidence of H3 K27M mutations in posterior fossa ependymomas
Gessi M, Capper D, Sahm F, Huang K, von Deimling A, Tippelt S, Fleischhack G, Scherbaum D, Alfer J, Juhnke B, von Hoff K, Rutkowski S, Warmuth-Metz M, Chavez L, Pfister S, Pietsch T, Jones D, Sturm D
ACTA NEUROPATHOL. 2016;132(4):635-7.

Childhood medulloblastoma
Massimino M, Biassoni V, Gandola L, Garrè M, Gatta G, Giangaspero F, Poggi G, Rutkowski S
CRIT REV ONCOL HEMAT. 2016;105:35-51.

Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors
Pajtler K, Tippelt S, Siegler N, Reichling S, Zimmermann M, Mikasch R, Bode U, Gnekow A, Pietsch T, Benesch M, Rutkowski S, Fleischhack G
J NEURO-ONCOL. 2016;128(3):463-71.

Reply to letter that comments on 'Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma
Pompe R, von Bueren A, Mynarek M, von Hoff K, Rutkowski S
EUR J CANCER. 2016;56:181-2.

Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis
Ramaswamy V, Hielscher T, Mack S, Lassaletta A, Lin T, Pajtler K, Jones D, Luu B, Cavalli F, Aldape K, Remke M, Mynarek M, Rutkowski S, Gururangan S, McLendon R, Lipp E, Dunham C, Hukin J, Eisenstat D, Fulton D, van Landeghem F, Santi M, van Veelen M, Van Meir E, Osuka S, Fan X, Muraszko K, Tirapelli D, Oba-Shinjo S, Marie S, Carlotti C, Lee J, Rao A, Giannini C, Faria C, Nunes S, Mora J, Hamilton R, Hauser P, Jabado N, Petrecca K, Jung S, Massimi L, Zollo M, Cinalli G, Bognár L, Klekner A, Hortobágyi T, Leary S, Ermoian R, Olson J, Leonard J, Gardner C, Grajkowska W, Chambless L, Cain J, Eberhart C, Ahsan S, Massimino M, Giangaspero F, Buttarelli F, Packer R, Emery L, Yong W, Soto H, Liau L, Everson R, Grossbach A, Shalaby T, Grotzer M, Karajannis M, Zagzag D, Wheeler H, von Hoff K, Alonso M, Tuñon T, Schüller U, Zitterbart K, Sterba J, Chan J, Guzman M, Elbabaa S, Colman H, Dhall G, Fisher P, Fouladi M, Gajjar A, Goldman S, Hwang E, Kool M, Ladha H, Vera-Bolanos E, Wani K, Lieberman F, Mikkelsen T, Omuro A, Pollack I, Prados M, Robins H, Soffietti R, Wu J, Metellus P, Tabori U, Bartels U, Bouffet E, Hawkins C, Rutka J, Dirks P, Pfister S, Merchant T, Gilbert M, Armstrong T, Korshunov A, Ellison D, Taylor M
J CLIN ONCOL. 2016;34(21):2468-77.

Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford S, Doz F, Kool M, Dufour C, Vassal G, Milde T, Witt O, von Hoff K, Pietsch T, Northcott P, Gajjar A, Robinson G, Padovani L, André N, Massimino M, Pizer B, Packer R, Rutkowski S, Pfister S, Taylor M, Pomeroy S
ACTA NEUROPATHOL. 2016;131(6):821-31.

Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study
Sabel M, Fleischhack G, Tippelt S, Gustafsson G, Doz F, Kortmann R, Massimino M, Navajas A, von Hoff K, Rutkowski S, Warmuth-Metz M, Clifford S, Pietsch T, Pizer B, Lannering B
J NEURO-ONCOL. 2016;129(3):515-24.

New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs
Sturm D, Orr B, Toprak U, Hovestadt V, Jones D, Capper D, Sill M, Buchhalter I, Northcott P, Leis I, Ryzhova M, Koelsche C, Pfaff E, Allen S, Balasubramanian G, Worst B, Pajtler K, Brabetz S, Johann P, Sahm F, Reimand J, Mackay A, Carvalho D, Remke M, Phillips J, Perry A, Cowdrey C, Drissi R, Fouladi M, Giangaspero F, Łastowska M, Grajkowska W, Scheurlen W, Pietsch T, Hagel C, Gojo J, Lötsch D, Berger W, Slavc I, Haberler C, Jouvet A, Holm S, Hofer S, Prinz M, Keohane C, Fried I, Mawrin C, Scheie D, Mobley B, Schniederjan M, Santi M, Buccoliero A, Dahiya S, Kramm C, von Bueren A, von Hoff K, Rutkowski S, Herold-Mende C, Frühwald M, Milde T, Hasselblatt M, Wesseling P, Rößler J, Schüller U, Ebinger M, Schittenhelm J, Frank S, Grobholz R, Vajtai I, Hans V, Schneppenheim R, Zitterbart K, Collins V, Aronica E, Varlet P, Puget S, Dufour C, Grill J, Figarella-Branger D, Wolter M, Schuhmann M, Shalaby T, Grotzer M, van Meter T, Monoranu C, Felsberg J, Reifenberger G, Snuderl M, Forrester L, Koster J, Versteeg R, Volckmann R, van Sluis P, Wolf S, Mikkelsen T, Gajjar A, Aldape K, Moore A, Taylor M, Jones C, Jabado N, Karajannis M, Eils R, Schlesner M, Lichter P, von Deimling A, Pfister S, Ellison D, Korshunov A, Kool M
CELL. 2016;164(5):1060-72.

Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors
Torchia J, Golbourn B, Feng S, Ho K, Sin-Chan P, Vasiljevic A, Norman J, Guilhamon P, Garzia L, Agamez N, Lu M, Chan T, Picard D, de Antonellis P, Khuong-Quang D, Planello A, Zeller C, Barsyte-Lovejoy D, Lafay-Cousin L, Letourneau L, Bourgey M, Yu M, Gendoo D, Dzamba M, Barszczyk M, Medina T, Riemenschneider A, Morrissy A, Ra Y, Ramaswamy V, Remke M, Dunham C, Yip S, Ng H, Lu J, Mehta V, Albrecht S, Pimentel J, Chan J, Somers G, Faria C, Roque L, Fouladi M, Hoffman L, Moore A, Wang Y, Choi S, Hansford J, Catchpoole D, Birks D, Foreman N, Strother D, Klekner A, Bognár L, Garami M, Hauser P, Hortobágyi T, Wilson B, Hukin J, Carret A, Van Meter T, Hwang E, Gajjar A, Chiou S, Nakamura H, Toledano H, Fried I, Fults D, Wataya T, Fryer C, Eisenstat D, Scheinemann K, Fleming A, Johnston D, Michaud J, Zelcer S, Hammond R, Afzal S, Ramsay D, Sirachainan N, Hongeng S, Larbcharoensub N, Grundy R, Lulla R, Fangusaro J, Druker H, Bartels U, Grant R, Malkin D, McGlade C, Nicolaides T, Tihan T, Phillips J, Majewski J, Montpetit A, Bourque G, Bader G, Reddy A, Gillespie G, Warmuth-Metz M, Rutkowski S, Tabori U, Lupien M, Brudno M, Schüller U, Pietsch T, Judkins A, Hawkins C, Bouffet E, Kim S, Dirks P, Taylor M, Erdreich-Epstein A, Arrowsmith C, De Carvalho D, Rutka J, Jabado N, Huang A
CANCER CELL. 2016;30(6):891-908.

Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters
von Bueren A, Kortmann R, von Hoff K, Friedrich C, Mynarek M, Müller K, Goschzik T, Zur Mühlen A, Gerber N, Warmuth-Metz M, Soerensen N, Deinlein F, Benesch M, Zwiener I, Kwiecien R, Faldum A, Bode U, Fleischhack G, Hovestadt V, Kool M, Jones D, Northcott P, Kuehl J, Pfister S, Pietsch T, Rutkowski S
J CLIN ONCOL. 2016;34(34):4151-4160.

2015

Neuropsychological Outcome of Children Treated for Standard Risk Medulloblastoma in the PNET4 European Randomized Controlled Trial of Hyperfractionated Versus Standard Radiation Therapy and Maintenance Chemotherapy
Câmara-Costa H, Resch A, Kieffer V, Lalande C, Poggi G, Kennedy C, Bull K, Calaminus G, Grill J, Doz F, Rutkowski S, Massimino M, Kortmann R, Lannering B, Dellatolas G, Chevignard M
INT J RADIAT ONCOL. 2015;92(5):978-85.

Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial
Clifford S, Lannering B, Schwalbe E, Hicks D, O'Toole K, Nicholson S, Goschzik T, Zur Mühlen A, Figarella-Branger D, Doz F, Rutkowski S, Gustafsson G, Pietsch T
ONCOTARGET. 2015;6(36):38827-39.

Primitive neuroectodermal tumors of the brainstem in children treated according to the HIT Trials: clinical findings of a rare disease
Friedrich C, Warmuth-Metz M, von Bueren A, Nowak J, Bison B, von Hoff K, Pietsch T, Kortmann R, Rutkowski S
J NEUROSURG-PEDIATR. 2015;15(3):227-35.

Molecular stratification of medulloblastoma: Comparison of histological and genetic methods to detect Wnt activated tumors
Goschzik T, Zur Mühlen A, Kristiansen G, Haberler C, Stefanits H, Friedrich C, von Hoff K, Rutkowski S, Pfister S, Pietsch T
NEUROPATH APPL NEURO. 2015;41(2):135-144.

Systematic comparison of MRI findings in pediatric ependymoblastoma with ependymoma and CNS primitive neuroectodermal tumor not otherwise specified
Nowak J, Seidel C, Pietsch T, Alkonyi B, Fuss T, Friedrich C, von Hoff K, Rutkowski S, Warmuth-Metz M
NEURO-ONCOLOGY. 2015;17(8):1157-65.

Neuropsychological short assessment of disease- and treatment-related intelligence deficits in children with brain tumours
Ottensmeier H, Zimolong B, Wolff J, Ehrich J, Galley N, von Hoff K, Kuehl J, Rutkowski S
EUR J PAEDIATR NEURO. 2015;19(3):298-307.

Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups
Pajtler K, Witt H, Sill M, Jones D, Hovestadt V, Kratochwil F, Wani K, Tatevossian R, Punchihewa C, Johann P, Reimand J, Warnatz H, Ryzhova M, Mack S, Ramaswamy V, Capper D, Schweizer L, Sieber L, Wittmann A, Huang Z, van Sluis P, Volckmann R, Koster J, Versteeg R, Fults D, Toledano H, Avigad S, Hoffman L, Donson A, Foreman N, Hewer E, Zitterbart K, Gilbert M, Armstrong T, Gupta N, Allen J, Karajannis M, Zagzag D, Hasselblatt M, Kulozik A, Witt O, Collins V, von Hoff K, Rutkowski S, Pietsch T, Bader G, Yaspo M, von Deimling A, Lichter P, Taylor M, Gilbertson R, Ellison D, Aldape K, Korshunov A, Kool M, Pfister S
CANCER CELL. 2015;27(5):728-43.

Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy
Pompe R, von Bueren A, Mynarek M, von Hoff K, Friedrich C, Kwiecien R, Treulieb W, Lindow C, Deinlein F, Fleischhack G, Kuehl J, Rutkowski S
EUR J CANCER. 2015;51(17):2634-2642.

Strategies to improve the quality of survival for childhood brain tumour survivors
Tallen G, Resch A, Calaminus G, Wiener A, Leiss U, Pletschko T, Friedrich C, Langer T, Grabow D, Driever P, Kortmann R, Timmermann B, Pietsch T, Warmuth-Metz M, Bison B, Thomale U, Krauss J, Mynarek M, von Hoff K, Ottensmeier H, Frühwald M, Kramm C, Temming P, Müller H, Witt O, Kordes U, Fleischhack G, Gnekow A, Rutkowski S
EUR J PAEDIATR NEURO. 2015;19(6):619-39.

Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis
Torchia J, Picard D, Lafay-Cousin L, Hawkins C, Kim S, Letourneau L, Ra Y, Ho K, Chan T, Sin-Chan P, Dunham C, Yip S, Ng H, Lu J, Albrecht S, Pimentel J, Chan J, Somers G, Zielenska M, Faria C, Roque L, Baskin B, Birks D, Foreman N, Strother D, Klekner A, Garami M, Hauser P, Hortobágyi T, Bognár L, Wilson B, Hukin J, Carret A, Van Meter T, Nakamura H, Toledano H, Fried I, Fults D, Wataya T, Fryer C, Eisenstat D, Scheineman K, Johnston D, Michaud J, Zelcer S, Hammond R, Ramsay D, Fleming A, Lulla R, Fangusaro J, Sirachainan N, Larbcharoensub N, Hongeng S, Barakzai M, Montpetit A, Stephens D, Grundy R, Schüller U, Nicolaides T, Tihan T, Phillips J, Taylor M, Rutka J, Dirks P, Bader G, Warmuth-Metz M, Rutkowski S, Pietsch T, Judkins A, Jabado N, Bouffet E, Huang A
LANCET ONCOL. 2015;16(5):569-82.

Incidence, Trends, and Survival of Children With Embryonal Tumors
Tulla M, Berthold F, Graf N, Rutkowski S, von Schweinitz D, Spix C, Kaatsch P
PEDIATRICS. 2015;136(3):e623-32.

Metastatic medulloblastoma in adults: outcome of patients treated according to the HIT2000 protocol
von Bueren A, Friedrich C, von Hoff K, Kwiecien R, Müller K, Pietsch T, Warmuth-Metz M, Hau P, Benesch M, Kuehl J, Kortmann R, Rutkowski S
EUR J CANCER. 2015;51(16):2434-43.

2014

Treatment of recurrent primitive neuroectodermal tumors (PNET) in children and adolescents with high-dose chemotherapy (HDC) and stem cell Support: results of the HITREZ 97 multicentre trial
Bode U, Zimmermann M, Moser O, Rutkowski S, Warmuth-Metz M, Pietsch T, Kortmann R, Faldum A, Fleischhack G
J NEURO-ONCOL. 2014;120(3):635-42.

Adults with CNS primitive neuroectodermal tumors/pineoblastomas: results of multimodal treatment according to the pediatric HIT 2000 protocol
Friedrich C, Müller K, von Hoff K, Kwiecien R, Pietsch T, Warmuth-Metz M, Gerber N, Hau P, Kuehl J, Kortmann R, von Bueren A, Rutkowski S
J NEURO-ONCOL. 2014;116(3):567-575.

Recent developments and current concepts in medulloblastoma
Gerber N, Mynarek M, von Hoff K, Friedrich C, Resch A, Rutkowski S
CANCER TREAT REV. 2014;40(3):356-365.

Treatment of children with central nervous system primitive neuroectodermal tumors/pinealoblastomas in the prospective multicentric trial HIT 2000 using hyperfractionated radiation therapy followed by maintenance chemotherapy
Gerber N, von Hoff K, Resch A, Ottensmeier H, Kwiecien R, Faldum A, Matuschek C, Hornung D, Bremer M, Benesch M, Pietsch T, Warmuth-Metz M, Kuehl J, Rutkowski S, Kortmann R
INT J RADIAT ONCOL. 2014;89(4):863-71.

MYCN amplification predicts poor outcome for patients with supratentorial primitive neuroectodermal tumors of the central nervous system
Gessi M, von Bueren A, Treszl A, Mühlen A, Hartmann W, Warmuth-Metz M, Rutkowski S, Pietsch T
NEURO-ONCOLOGY. 2014;16(7):924-932.

Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group
Gottardo N, Hansford J, McGlade J, Alvaro F, Ashley D, Bailey S, Baker D, Bourdeaut F, Cho Y, Clay M, Clifford S, Cohn R, Cole C, Dallas P, Downie P, Doz F, Ellison D, Endersby R, Fisher P, Hassall T, Heath J, Hii H, Jones D, Junckerstorff R, Kellie S, Kool M, Kotecha R, Lichter P, Laughton S, Lee S, McCowage G, Northcott P, Olson J, Packer R, Pfister S, Pietsch T, Pizer B, Pomeroy S, Remke M, Robinson G, Rutkowski S, Schoep T, Shelat A, Stewart C, Sullivan M, Taylor M, Wainwright B, Walwyn T, Weiss W, Williamson D, Gajjar A
ACTA NEUROPATHOL. 2014;127(2):189-201.

Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing
Hovestadt V, Jones D, Picelli S, Wang W, Kool M, Northcott P, Sultan M, Stachurski K, Ryzhova M, Warnatz H, Ralser M, Brun S, Bunt J, Jäger N, Kleinheinz K, Erkek S, Weber U, Bartholomae C, von Kalle C, Lawerenz C, Eils J, Koster J, Versteeg R, Milde T, Witt O, Schmidt S, Wolf S, Pietsch T, Rutkowski S, Scheurlen W, Taylor M, Brors B, Felsberg J, Reifenberger G, Borkhardt A, Lehrach H, Wechsler-Reya R, Eils R, Yaspo M, Landgraf P, Korshunov A, Zapatka M, Radlwimmer B, Pfister S, Lichter P
NATURE. 2014;510(7506):537-541.

Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma
Kennedy C, Bull K, Chevignard M, Culliford D, Dörr H, Doz F, Kortmann R, Lannering B, Massimino M, Navajas Gutiérrez A, Rutkowski S, Spoudeas H, Calaminus G
INT J RADIAT ONCOL. 2014;88(2):292-300.

Postponed is not canceled: role of craniospinal radiation therapy in the management of recurrent infant medulloblastoma--an experience from the HIT-REZ 1997 & 2005 studies
Müller K, Mynarek M, Zwiener I, Siegler N, Zimmermann M, Christiansen H, Budach W, Henke G, Warmuth-Metz M, Pietsch T, von Hoff K, von Bueren A, Bode U, Rutkowski S, Kortmann R, Fleischhack G, Tippelt S
INT J RADIAT ONCOL. 2014;88(5):1019-1024.

Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma
Northcott P, Lee C, Zichner T, Stütz A, Erkek S, Kawauchi D, Shih D, Hovestadt V, Zapatka M, Sturm D, Jones D, Kool M, Remke M, Cavalli F, Zuyderduyn S, Bader G, VandenBerg S, Esparza L, Ryzhova M, Wang W, Wittmann A, Stark S, Sieber L, Seker-Cin H, Linke L, Kratochwil F, Jäger N, Buchhalter I, Imbusch C, Zipprich G, Raeder B, Schmidt S, Diessl N, Wolf S, Wiemann S, Brors B, Lawerenz C, Eils J, Warnatz H, Risch T, Yaspo M, Weber U, Bartholomae C, von Kalle C, Turányi E, Hauser P, Sanden E, Darabi A, Siesjö P, Sterba J, Zitterbart K, Sumerauer D, van Sluis P, Versteeg R, Volckmann R, Koster J, Schuhmann M, Ebinger M, Grimes H, Robinson G, Gajjar A, Mynarek M, von Hoff K, Rutkowski S, Pietsch T, Scheurlen W, Felsberg J, Reifenberger G, Kulozik A, von Deimling A, Witt O, Eils R, Gilbertson R, Korshunov A, Taylor M, Lichter P, Korbel J, Wechsler-Reya R, Pfister S
NATURE. 2014;511(7510):428-434.

Hypertrophic olivary degeneration with gadolinium enhancement after posterior fossa surgery in a child with medulloblastoma
Nowak J, Alkonyi B, Rutkowski S, Homola G, Warmuth-Metz M
CHILD NERV SYST. 2014;30(5):959-62.

MRI Characteristics of Ependymoblastoma: Results from 22 Centrally Reviewed Cases
Nowak J, Seidel C, Berg F, Pietsch T, Friedrich C, von Hoff K, Rutkowski S, Warmuth-Metz M
AM J NEURORADIOL. 2014;35(10):1996-2001.

Ependymoblastoma of the brainstem: MRI findings and differential diagnosis
Nowak J, Seidel C, Pietsch T, Friedrich C, von Hoff K, Rutkowski S, Warmuth-Metz M
PEDIATR BLOOD CANCER. 2014;61(6):1132-1134.

Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort
Pietsch T, Schmidt R, Remke M, Korshunov A, Hovestadt V, Jones D, Felsberg J, Kaulich K, Goschzik T, Kool M, Northcott P, von Hoff K, von Bueren A, Friedrich C, Mynarek M, Skladny H, Fleischhack G, Taylor M, Cremer F, Lichter P, Faldum A, Reifenberger G, Rutkowski S, Pfister S
ACTA NEUROPATHOL. 2014;128(1):137-149.

Neuroonkologie
Rutkowski S, Hornung D, Kordes U, Kammler G, Hagel C, Löbel U, Ebinger M, Rössler J, Resch A, Linhart D
2014. Neuropädiatrie - Evidenzbasierte Therapie. Korinthenberg R, Panteliadis C, Hagel C (Hrsg.). 2. Aufl. München: Elsevier, .

Feasibility of intensive multimodal therapy in infants affected by rhabdoid tumors - experience of the EU-RHAB registry
Seeringer A, Bartelheim K, Kerl K, Hasselblatt M, Leuschner I, Rutkowski S, Timmermann B, Kortmann R, Koscielniak E, Schneppenheim R, Warmuth-Metz M, Gerß J, Siebert R, Graf N, Boos J, Frühwald M
KLIN PADIATR. 2014;226(3):143-148.

Cytogenetic prognostication within medulloblastoma subgroups
Shih D, Northcott P, Remke M, Korshunov A, Ramaswamy V, Kool M, Luu B, Yao Y, Wang X, Dubuc A, Garzia L, Peacock J, Mack S, Wu X, Rolider A, Morrissy A, Cavalli F, Jones D, Zitterbart K, Faria C, Schüller U, Kren L, Kumabe T, Tominaga T, Shin Ra Y, Garami M, Hauser P, Chan J, Robinson S, Bognár L, Klekner A, Saad A, Liau L, Albrecht S, Fontebasso A, Cinalli G, De Antonellis P, Zollo M, Cooper M, Thompson R, Bailey S, Lindsey J, Di Rocco C, Massimi L, Michiels E, Scherer S, Phillips J, Gupta N, Fan X, Muraszko K, Vibhakar R, Eberhart C, Fouladi M, Lach B, Jung S, Wechsler-Reya R, Fèvre-Montange M, Jouvet A, Jabado N, Pollack I, Weiss W, Lee J, Cho B, Kim S, Wang K, Leonard J, Rubin J, de Torres C, Lavarino C, Mora J, Cho Y, Tabori U, Olson J, Gajjar A, Packer R, Rutkowski S, Pomeroy S, French P, Kloosterhof N, Kros J, Van Meir E, Clifford S, Bourdeaut F, Delattre O, Doz F, Hawkins C, Malkin D, Grajkowska W, Perek-Polnik M, Bouffet E, Rutka J, Pfister S, Taylor M
J CLIN ONCOL. 2014;32(9):886-896.

Subgroup-specific localization of human medulloblastoma based on pre-operative MRI
Wefers A, Warmuth-Metz M, Pöschl J, von Bueren A, Monoranu C, Seelos K, Peraud A, Tonn J, Koch A, Pietsch T, Herold-Mende C, Mawrin C, Schouten-van Meeteren A, van Vuurden D, von Hoff K, Rutkowski S, Pfister S, Kool M, Schüller U
ACTA NEUROPATHOL. 2014;127(6):931-3.

WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma
Zhukova N, Ramaswamy V, Remke M, Martin D, Castelo-Branco P, Zhang C, Fraser M, Tse K, Poon R, Shih D, Baskin B, Ray P, Bouffet E, Dirks P, von Bueren A, Pfaff E, Korshunov A, Jones D, Northcott P, Kool M, Pugh T, Pomeroy S, Cho Y, Pietsch T, Gessi M, Rutkowski S, Bognár L, Cho B, Eberhart C, Conter C, Fouladi M, French P, Grajkowska W, Gupta N, Hauser P, Jabado N, Vasiljevic A, Jung S, Kim S, Klekner A, Kumabe T, Lach B, Leonard J, Liau L, Massimi L, Pollack I, Ra Y, Rubin J, Van Meir E, Wang K, Weiss W, Zitterbart K, Bristow R, Alman B, Hawkins C, Malkin D, Clifford S, Pfister S, Taylor M, Tabori U
Acta Neuropathol Comm. 2014;2:174.

2013

Primary intracranial soft tissue sarcoma in children and adolescents: a cooperative analysis of the European CWS and HIT study groups
Benesch M, von Bueren A, Dantonello T, von Hoff K, Pietsch T, Leuschner I, Claviez A, Bierbach U, Kropshofer G, Korinthenberg R, Graf N, Suttorp M, Kortmann R, Friedrich C, von der Weid N, Kaatsch P, Klingebiel T, Koscielniak E, Rutkowski S
J NEURO-ONCOL. 2013;111(3):337-345.

Treatment of young children with CNS-primitive neuroectodermal tumors/pineoblastomas in the prospective multicenter trial HIT 2000 using different chemotherapy regimens and radiotherapy.
Friedrich C, von Bueren A, von Hoff K, Gerber N, Ottensmeier H, Deinlein F, Benesch M, Kwiecien R, Pietsch T, Warmuth-Metz M, Faldum A, Kuehl J, Kortmann R, Rutkowski S
NEURO-ONCOLOGY. 2013;15(2):224-234.

Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: a prospective observational multicentre study
Friedrich C, von Bueren A, von Hoff K, Kwiecien R, Pietsch T, Warmuth-Metz M, Hau P, Deinlein F, Kuehl J, Kortmann R, Rutkowski S
EUR J CANCER. 2013;49(4):893-903.

Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays
Hovestadt V, Remke M, Kool M, Pietsch T, Northcott P, Fischer R, Cavalli F, Ramaswamy V, Zapatka M, Reifenberger G, Rutkowski S, Schick M, Bewerunge-Hudler M, Korshunov A, Lichter P, Taylor M, Pfister S, Jones D
ACTA NEUROPATHOL. 2013;125(6):913-6.

What's in a name? Intracranial peripheral primitive neuroectodermal tumors and CNS primitive neuroectodermal tumors are not the same
Müller K, Diez B, Muggeri A, Pietsch T, Friedrich C, Rutkowski S, von Hoff K, von Bueren A, Zwiener I, Bruns F
STRAHLENTHER ONKOL. 2013;189(5):372-9.

Somatostatin receptor subtype 2 (sst₂) is a potential prognostic marker and a therapeutic target in medulloblastoma
Remke M, Hering E, Gerber N, Kool M, Sturm D, Rickert C, Gerß J, Schulz S, Hielscher T, Hasselblatt M, Jeibmann A, Hans V, Ramaswamy V, Taylor M, Pietsch T, Rutkowski S, Korshunov A, Monoranu C, Frühwald M
CHILD NERV SYST. 2013;29(8):1253-62.

TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma
Remke M, Ramaswamy V, Peacock J, Shih D, Koelsche C, Northcott P, Hill N, Cavalli F, Kool M, Wang X, Mack S, Barszczyk M, Morrissy A, Wu X, Agnihotri S, Luu B, Jones D, Garzia L, Dubuc A, Zhukova N, Vanner R, Kros J, French P, Van Meir E, Vibhakar R, Zitterbart K, Chan J, Bognár L, Klekner A, Lach B, Jung S, Saad A, Liau L, Albrecht S, Zollo M, Cooper M, Thompson R, Delattre O, Bourdeaut F, Doz F, Garami M, Hauser P, Carlotti C, Van Meter T, Massimi L, Fults D, Pomeroy S, Kumabe T, Ra Y, Leonard J, Elbabaa S, Mora J, Rubin J, Cho Y, McLendon R, Bigner D, Eberhart C, Fouladi M, Wechsler-Reya R, Faria C, Croul S, Huang A, Bouffet E, Hawkins C, Dirks P, Weiss W, Schüller U, Pollack I, Rutkowski S, Meyronet D, Jouvet A, Fèvre-Montange M, Jabado N, Perek-Polnik M, Grajkowska W, Kim S, Rutka J, Malkin D, Tabori U, Pfister S, Korshunov A, von Deimling A, Taylor M
ACTA NEUROPATHOL. 2013;126(6):917-29.

Effective childhood cancer Treatment: the impact of large scale clinical trials in Germany and Austria
Rossig C, Juergens H, Schrappe M, Moericke A, Henze G, von Stackelberg A, Reinhardt D, Burkhardt B, Woessmann W, Zimmermann M, Gadner H, Mann G, Schellong G, Mauz-Koerholz C, Dirksen U, Bielack S, Berthold F, Graf N, Rutkowski S, Calaminus G, Kaatsch P, Creutzig U
PEDIATR BLOOD CANCER. 2013;60(10):1574-81.

A very rare cancer in Down Syndrome: medulloblastoma. Epidemiological data from 13 countries
Satgé D, Stiller C, Rutkowski S, von Bueren A, Lacour B, Sommelet D, Nishi M, Massimino M, Garré M, Moreno F, Hasle H, Jakab Z, Greenberg M, von der Weid N, Kuehni C, Zurriaga O, Vicente M, Peris-Bonet R, Benesch M, Vekemans M, Sullivan S, Rickert C
J NEURO-ONCOL. 2013;112(1):107-14.

Infantile malignant brain tumors
von Hoff K, Rutkowski S
2013. Tumors of the pediatric central nervous system. Keating R, Tait Goodrich J, Packer R (Hrsg.). 2.. Aufl. New York: Georg Thieme Verlag , .

Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group
Warren K, Poussaint T, Vezina G, Hargrave D, Packer R, Goldman S, Wen P, Pollack I, Zurakowski D, Kun L, Prados M, Rutkowski S, Kieran M
PEDIATR BLOOD CANCER. 2013;60(9):1397-401.

Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma
Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih D, Martin D, Castelo-Branco P, Baskin B, Ray P, Bouffet E, von Bueren A, Jones D, Northcott P, Kool M, Sturm D, Pugh T, Pomeroy S, Cho Y, Pietsch T, Gessi M, Rutkowski S, Bognar L, Klekner A, Cho B, Kim S, Wang K, Eberhart C, Fevre-Montange M, Fouladi M, French P, Kros M, Grajkowska W, Gupta N, Weiss W, Hauser P, Jabado N, Jouvet A, Jung S, Kumabe T, Lach B, Leonard J, Rubin J, Liau L, Massimi L, Pollack I, Shin Ra Y, Van Meir E, Zitterbart K, Schüller U, Hill R, Lindsey J, Schwalbe E, Bailey S, Ellison D, Hawkins C, Malkin D, Clifford S, Korshunov A, Pfister S, Taylor M, Tabori U
J CLIN ONCOL. 2013;31(23):2927-35.

2012

Proper cerebellar development requires expression of β1-integrin in Bergmann glia, but not in granule neurons.
Frick A, Grammel D, Schmidt F, Pöschl J, Priller M, Pagella P, von Bueren A, André O, Peraud A, Tonn J, Rutkowski S, Rutkowski S, Kretzschmar H, Schüller U
GLIA. 2012;60(5):820-832.

A long duration of the prediagnostic symptomatic interval is not associated with an unfavourable prognosis in childhood medulloblastoma.
Gerber N, von Hoff K, von Bueren A, Treulieb W, Treulieb W, Deinlein F, Benesch M, Zwiener I, Soerensen N, Warmuth-Metz M, Pietsch T, Mittler U, Kuehl J, Kortmann R, Rutkowski S, Rutkowski S
EUR J CANCER. 2012;48(13):2028-2036.

p53 expression predicts dismal outcome for medulloblastoma patients with metastatic disease.
Gessi M, von Bueren A, Rutkowski S, Rutkowski S, Pietsch T
J NEURO-ONCOL. 2012;106(1):135-141.

Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem.
Grammel D, Warmuth-Metz M, von Bueren A, André O, Kool M, Pietsch T, Kretzschmar H, Rutkowski S, Rutkowski S, Pfister S, Schüller U
ACTA NEUROPATHOL. 2012;123(4):601-614.

Targeted therapeutics in treatment of children and young adults with solid tumors: an expert survey and review of the literature.
Grunewald T, Greulich N, Kontny U, Frühwald M, Rutkowski S, Kordes U, Scheurlen W, Schmidt W, Stachel D, Metzler M, Mittler U, Graf N, Benesch M, Burdach S
KLIN PADIATR. 2012;224(3):124-131.

Dissecting the genomic complexity underlying medulloblastoma.
Jones D, Jäger N, Kool M, Zichner T, Hutter B, Sultan M, Cho Y, Pugh T, Hovestadt V, Stütz A, Rausch T, Warnatz H, Ryzhova M, Bender S, Sturm D, Pleier S, Cin H, Pfaff E, Sieber L, Wittmann A, Remke M, Witt H, Hutter S, Tzaridis T, Weischenfeldt J, Raeder B, Avci M, Amstislavskiy V, Zapatka M, Weber U, Wang Q, Lasitschka B, Bartholomae C, Schmidt M, von Kalle C, Ast V, Lawerenz C, Eils J, Kabbe R, Benes V, van Sluis P, Koster J, Volckmann R, Shih D, Betts M, Russell R, Coco S, Tonini G, Schüller U, Hans V, Graf N, Kim Y, Monoranu C, Roggendorf W, Unterberg A, Herold-Mende C, Milde T, Kulozik A, von Deimling A, Witt O, Maass E, Rössler J, Ebinger M, Schuhmann M, Frühwald M, Hasselblatt M, Jabado N, Rutkowski S, von Bueren A, André O, Williamson D, Clifford S, McCabe M, Collins V, Wolf S, Wiemann S, Lehrach H, Brors B, Scheurlen W, Felsberg J, Reifenberger G, Northcott P, Taylor M, Meyerson M, Pomeroy S, Yaspo M, Korbel J, Korshunov A, Eils R, Pfister S, Lichter P
NATURE. 2012;488(7409):100-105.

Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.
Kool M, Korshunov A, Remke M, Jones D, Schlanstein M, Northcott P, Cho Y, Koster J, Antoinette S, van Vuurden D, Clifford S, Pietsch T, von Bueren A, Rutkowski S, Rutkowski S, McCabe M, Collins V, Bäcklund M, Haberler C, Bourdeaut F, Delattre O, Doz F, Ellison D, Gilbertson R, Pomeroy S, Taylor M, Lichter P, Pfister S
ACTA NEUROPATHOL. 2012;123(4):473-484.

Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial.
Lannering B, Rutkowski S, Doz F, Pizer B, Gustafsson G, Navajas A, Massimino M, Reddingius R, Benesch M, Carrie C, Taylor R, Gandola L, Björk-Eriksson T, Giralt J, Oldenburger F, Pietsch T, Figarella-Branger D, Robson K, Forni M, Clifford S, Warmuth-Metz M, von Hoff K, Faldum A, Mosseri V, Kortmann R
J CLIN ONCOL. 2012;30(26):3187-3193.

Molecular subgroups of medulloblastoma: the current consensus.
Taylor M, Northcott P, Korshunov A, Remke M, Cho Y, Clifford S, Eberhart C, Parsons D, Rutkowski S, Gajjar A, Ellison D, Lichter P, Gilbertson R, Pomeroy S, Kool M, Pfister S
ACTA NEUROPATHOL. 2012;123(4):465-472.

DNA copy number alterations in central primitive neuroectodermal tumors and tumors of the pineal region: an international individual patient data meta-analysis.
von Bueren A, André O, Hagel C, Hagel C, Cai H, Remke M, Hasselblatt M, Feuerstein B, Pernet S, Delattre O, Rutkowski S, Rutkowski S, Pfister S, Baudis M
J NEURO-ONCOL. 2012;109(2):415-423.

Mismatch repair deficiency
von Bueren A, Bacolod M, Hagel C, Heinimann K, Fedier A, Kordes U, Pietsch T, Koster J, Grotzer M, Friedman H, Marra G, Kool M, Rutkowski S
BRIT J CANCER. 2012;107(8):1399-408.

Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.
von Bueren A, Bacolod M, Hagel C, Heinimann K, Fedier A, Kordes U, Pietsch T, Koster J, Grotzer M, Friedman H, Marra G, Kool M, Rutkowski S
BRIT J CANCER. 2012;107(8):1399-1408.

Medulloblastoma.
von Hoff K, Rutkowski S
Curr Treat Options Neurol. 2012;14(4):416-426.

2011

Primary central nervous system primitive neuroectodermal tumors (CNS-PNETs) of the spinal cord in children: four cases from the German HIT database with a critical review of the literature.
Benesch M, Sperl D, von Bueren A, André O, von Hoff K, von Hoff K, Warmuth-Metz M, Ferrari R, Lassay L, Kortmann R, Rutkowski S, Rutkowski S
J NEURO-ONCOL. 2011;104(1):279-286.

Outcome of 11 children with ependymoblastoma treated within the prospective HIT-trials between 1991 and 2006.
Gerber N, von Hoff K, von Bueren A, Treulieb W, Treulieb W, Warmuth-Metz M, Pietsch T, Soerensen N, Faldum A, Emser A, Schlegel P, Deinlein F, Rutkowski S, Rutkowski S
J NEURO-ONCOL. 2011;102(3):459-469.

Ectopic craniopharyngioma.
Kordes U, Flitsch J, Hagel C, Goebell E, Schwarz R, Herberhold T, von Bueren A, Rutkowski S, Müller H
KLIN PADIATR. 2011;223(3):176-177.

Childhood medulloblastoma.
Massimino M, Giangaspero F, Garrè M, Gandola L, Poggi G, Biassoni V, Gatta G, Rutkowski S
CRIT REV ONCOL HEMAT. 2011;79(41):65-83.

Curative treatment for central nervous system medulloepithelioma despite residual disease after resection. Report of two cases treated according to the GPHO Protocol HIT 2000 and review of the literature.
Müller K, Zwiener I, Welker H, Maass E, Bongartz R, Berthold F, Pietsch T, Warmuth-Metz M, von Bueren A, Rutkowski S
STRAHLENTHER ONKOL. 2011;187(11):757-762.

The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells.
Oehler C, von Bueren A, André O, Furmanova P, Broggini-Tenzer A, Rutkowski S, Rutkowski S, Frei K, Grotzer M, Pruschy M
NEURO-ONCOLOGY. 2011;13(9):1000-1010.

Expression of BARHL1 in medulloblastoma is associated with prolonged survival in mice and humans.
Pöschl J, Lorenz A, Hartmann W, von Bueren A, Kool M, Li S, Peraud A, Tonn J, Herms J, Xiang M, Rutkowski S, Kretzschmar H, Schüller U
ONCOGENE. 2011;30(47):4721-4730.

Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients.
Priller M, Pöschl J, Abrão L, von Bueren A, André O, Rutkowski S, Rutkowski S, Kretzschmar H, Schüller U
CLIN CANCER RES. 2011;17(21):6791-6801.

FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma.
Remke M, Hielscher T, Korshunov A, Northcott P, Bender S, Kool M, Westermann F, Benner A, Cin H, Ryzhova M, Sturm D, Witt H, Haag D, Toedt G, Wittmann A, Schöttler A, von Bueren A, André O, Rutkowski S, Rutkowski S, Scheurlen W, Kulozik A, Taylor M, Lichter P, Pfister S
J CLIN ONCOL. 2011;29(29):3852-3861.

c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients.
von Bueren A, André O, Oehler C, von Hoff K, von Hoff K, Pruschy M, Seifert B, Gerber N, Warmuth-Metz M, Stearns D, Eberhart C, Rutkowski S, Rutkowski S, Grotzer M
BMC CANCER. 2011;11:74.

Late complete remission of supratentorial primitive neuroectodermal tumor (CNS-PNET) after multiple relapses.
von Bueren A, André O, Warmuth-Metz M, Schlegel P, Soerensen N, Krauss J, Roggendorf W, Pietsch T, Feiden W, Graf N, Pohl F, Flentje M, Rutkowski S, Rutkowski S
PEDIATR BLOOD CANCER. 2011;56(3):503-505.

Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology.
von Bueren A, von Hoff K, von Hoff K, Pietsch T, Gerber N, Warmuth-Metz M, Deinlein F, Zwiener I, Faldum A, Fleischhack G, Benesch M, Krauss J, Kuehl J, Rutkowski S, Rutkowski S
NEURO-ONCOLOGY. 2011;13(6):669-679.

Frequency, risk-factors and survival of children with atypical teratoid rhabdoid tumors (AT/RT) of the CNS diagnosed between 1988 and 2004, and registered to the German HIT database.
von Hoff K, Hinkes B, Dannenmann-Stern E, von Bueren A, André O, Warmuth-Metz M, Soerensen N, Emser A, Zwiener I, Schlegel P, Kuehl J, Frühwald M, Kortmann R, Rutkowski S, Rutkowski S
PEDIATR BLOOD CANCER. 2011;57(6):978-985.

Recurrence in childhood medulloblastoma.
Warmuth-Metz M, Blashofer S, von Bueren A, von Hoff K, von Hoff K, Bison B, Pohl F, Kortmann R, Rutkowski S, Rutkowski S
J NEURO-ONCOL. 2011;103(3):705-711.

High dose methotrexate for pediatric high grade glioma: results of the HIT-GBM-D Pilot study.
Wolff J, Kortmann R, Wolff B, Pietsch T, Peters O, Schmid H, Rutkowski S, Warmuth-Metz M, Kramm C
J NEURO-ONCOL. 2011;102(3):433-442.

2010

Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours.
Ardon H, Steven D, Frank V, Claes L, Kramm C, Rutkowski S, Wolff J, Gool V, Stefaan W
PEDIATR BLOOD CANCER. 2010;54(4):519-525.

Ependymoma of the spinal cord in children and adolescents: a retrospective series from the HIT database.
Benesch M, Weber-Mzell D, Gerber N, von Hoff K, Deinlein F, Krauss J, Warmuth-Metz M, Kortmann R, Pietsch T, Driever P, Quehenberger F, Urban C, Rutkowski S
J NEUROSURG-PEDIATR. 2010;6(2):137-144.

Non-cerebellar primitive neuroectodermal tumors (PNET): summary of the Milan consensus and state of the art workshop on marrow ablative chemotherapy with hematopoietic cell rescue for malignant brain tumors of childhood and adolescents.
Fangusaro J, Massimino M, Rutkowski S, Gururangan S
PEDIATR BLOOD CANCER. 2010;54(4):638-640.

Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
Korshunov A, Remke M, Werft W, Benner A, Ryzhova M, Witt H, Sturm D, Wittmann A, Schöttler A, Felsberg J, Reifenberger G, Rutkowski S, Scheurlen W, Kulozik A, von Deimling A, Lichter P, Pfister S
J CLIN ONCOL. 2010;28(18):3054-3060.

TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.
Pfaff E, Remke M, Sturm D, Benner A, Witt H, Till M, von Bueren A, André O, Wittmann A, Schöttler A, Jorch N, Graf N, Kulozik A, Witt O, Scheurlen W, Rutkowski S, Rutkowski S, Taylor M, Tabori U, Lichter P, Korshunov A, Pfister S
J CLIN ONCOL. 2010;28(35):5188-5196.

Medulloblastoma in young children.
Rutkowski S, Cohen B, Finlay J, Luksch R, Ridola V, Valteau-Couanet D, Hara J, Garre M, Grill J
PEDIATR BLOOD CANCER. 2010;54(4):635-637.

Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis.
Rutkowski S, von Hoff K, Emser A, Zwiener I, Pietsch T, Figarella-Branger D, Giangaspero F, Ellison D, Garre M, Biassoni V, Grundy R, Finlay J, Dhall G, Raquin M, Grill J
J CLIN ONCOL. 2010;28(33):4961-4968.

Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors.
von Hoff K, Hartmann W, von Bueren A, Oscar A, Gerber N, Grotzer M, Rutkowski S, Rutkowski S
PEDIATR BLOOD CANCER. 2010;54(3):369-376.

Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol.
Wolff J, Driever P, Erdlenbruch B, Kortmann R, Rutkowski S, Pietsch T, Parker C, Metz M, Gnekow A, Kramm C
CANCER-AM CANCER SOC. 2010;116(3):705-712.

Letzte Aktualisierung aus dem FIS: 17.07.2017 - 00:04 Uhr